High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)

被引：0
|
作者：
Sterrenberg, Danielle
Stiff, Patrick J.
Parthasarathy, Mala
Go, Aileen
Smith, Scott E.
Rodriguez, Tulio E.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.3376.3376
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3376
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PK-Directed Intravenous Busulfan in Combination with High-Dose Melphalan and Bortezomib As Conditioning Regimen for Patients with Multiple Myeloma
    Barta, Stefan Klaus
    Mazumder, Amitabha
    Carter, Jason
    Almanzar, Lawrence
    Elkind, Richard
    Battini, Ramakrishna
    Derman, Olga
    Kornblum, Noah
    Xue, Xionan
    Verma, Amit
    Braunschweig, Ira
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S104 - S105
  • [42] Full dose or reduced dose Melphalan (MEL) for autologous stem cell transplantation (ASCT) in multiple myeloma (MM): a single center analysis on 146 patients
    vom Hofe, F.
    Muegge, L-O
    Scholl, S.
    Hilgendorf, I
    Sayer, H.
    Yomade, O.
    Ernst, T.
    Hochhaus, A.
    von Lilienfeld-Toal, M.
    Brioli, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 184 - 184
  • [43] High dose chemotherapy (HDCT) followed by autologous stem cell transplantation (ASCT) in multiple myeloma (MM): An analysis of prognostic factors.
    Lalit, K
    Ganessan, K
    Wadhwa, J
    Sharma, A
    Kochupillai, V
    BLOOD, 2002, 100 (11) : 474B - 474B
  • [44] Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen
    Hagen, Patrick
    D'Souza, Anita
    Hari, Parameswaran
    Davila, Omar
    Zhang, Mei-Jie
    Vesole, David H.
    Smith, Scott E.
    Rodriguez, Tulio E.
    Stiff, Patrick J.
    LEUKEMIA & LYMPHOMA, 2020, 61 (14) : 3484 - 3492
  • [45] Addition of Bortezomib to High Dose Melphalan As Conditioning Regimen for Autologous Stem Cell Transplantation Improves the Response Rate in Newly Diagnosed Multiple Myeloma Patients
    Dalla Palma, Benedetta
    Prezioso, Lucia
    Accardi, Fabrizio
    Bisbano, Stefano
    De Luca, Federica
    Aversa, Franco
    Giuliani, Nicola
    BLOOD, 2016, 128 (22)
  • [46] Intensive therapy with bortezomib and melphalan and autologous stem cell transplantation for patients with multiple myeloma
    Luo, Y.
    Tan, Y.
    He, J.
    Shi, J.
    Wu, W.
    Han, X.
    Zheng, G.
    Wei, G.
    Zheng, W.
    Ye, X.
    Cai, Z.
    Huang, H.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S264 - S264
  • [47] Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (05) : 923 - 929
  • [48] Bortezomib-High Dose Melphalan Conditioning for the Treatment of MM Patients Undergoing ASCT
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Chaudhry, Ahsan
    Tay, Jason
    Luider, Joanne
    Bahlis, Nizar J.
    BLOOD, 2016, 128 (22)
  • [49] High-Dose Melphalan Versus Busulfan, Cyclophosphamide As Conditioning Regimens for Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma
    Styler, Michael
    Crilley, Pamela Ann
    Jain, Maneesh
    Ward, Kristine
    Topolsky, David
    Cho, David
    Kim, Marc
    BLOOD, 2015, 126 (23)
  • [50] BUSULFAN PLUS CYCLOPHOSPHAMIDE AND ETOPOSIDE VERSUS HIGH-DOSE MELPHALAN AS CONDITIONING IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA
    Park, Seonyang
    Lee, Youngjoon
    Lim, Sungnam
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 484 - 484
12345